Investigational drug · Phase 3
LBL-024
Not approved by FDA. In 11 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
11
11 still active
All registered trials
11
Any phase or sponsor naming "LBL-024"
First trial start
2022
Jan 6, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LBL-024", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Advanced Solid Tumour
- Advanced Extrapulmonary Neuroendocrine Carcinoma
- Metastatic Colorectal Carcinoma
- Ovarian Cancer
- Advanced Solid Tumor
- Triple Negative Breast Cancer
- Advanced Melanoma
- Advanced Neuroendocrine Carcinoma
Approved drugs for the same conditions: Breast cancer · Melanoma · Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "LBL-024" as an intervention, largest first.
Nanjing Leads Biolabs Co.,LtdIndustry
NCT05170958 · 396 participants (planned) · Start Jan 6, 2022 · Primary completion Dec 2026
Drug: LBL-024 for Injection · For: Advanced Solid Tumor
Sites: Hefei, China; Beijing, China; Chongqing, China · 49 sites in all
- A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal CarcinomaPivotal-lookingRecruiting
Nanjing Leads Biolabs Co.,LtdIndustry
NCT07791758 · 369 participants (planned) · Start Sep 28, 2026 · Primary completion Sep 4, 2030
Drug: LBL-024 for Injection; Bevacizumab injection and 3 more · For: Metastatic Colorectal Carcinoma
Sites: Guangzhou, China; Guilin, China; Nanning, China · 10 sites in all
- A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NECPivotal-lookingNot yet recruiting
Nanjing Leads Biolabs Co.,LtdIndustry
NCT07720193 · 280 participants (planned) · Start Nov 16, 2026 · Primary completion Dec 22, 2030
Drug: LBL-024 for Injection; Etoposide injection and 3 more · For: Advanced Extrapulmonary Neuroendocrine Carcinoma
Sites: Bengbu, China; Beijing, China; Chongqing, China · 36 sites in all
- A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.Pivotal-lookingRecruiting
Nanjing Leads Biolabs Co.,LtdIndustry
NCT07099430 · 280 participants (planned) · Start Sep 5, 2025 · Primary completion Oct 30, 2027
Drug: LBL-024 for Injection; Toripalimab Injection · For: Advanced Melanoma
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 16 sites in all
- A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]Pivotal-lookingRecruiting
Nanjing Leads Biolabs Co.,LtdIndustry
NCT06783647 · 250 participants (planned) · Start Jun 11, 2025 · Primary completion Dec 24, 2026
Drug: LBL-024 for Injection; Docetaxel Injection and 4 more · For: Advanced Solid Tumour
Sites: Hefei, China; Beijing, China; Fuzhou, China · 24 sites in all
- A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast CancerPivotal-lookingRecruiting
Nanjing Leads Biolabs Co.,LtdIndustry
NCT07281976 · 220 participants (planned) · Start Jan 27, 2026 · Primary completion Dec 31, 2027
Drug: LBL-024 for Injection; albumin-bound Paclitaxel injection and 1 more · For: Triple Negative Breast Cancer
Sites: Guangzhou, China; Harbin, China; Zhengzhou, China · 7 sites in all
- A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian CancerPivotal-lookingRecruiting
Nanjing Leads Biolabs Co.,LtdIndustry
NCT07042802 · 180 participants (planned) · Start Dec 2, 2025 · Primary completion Dec 25, 2027
Drug: LBL-024 for Injection; Paclitaxel injection and 1 more · For: Ovarian Cancer
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 13 sites in all
- A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine CarcinomaPivotal-lookingRecruiting
Nanjing Leads Biolabs Co.,LtdIndustry
NCT06157827 · 178 participants (planned) · Start Dec 8, 2023 · Primary completion Dec 28, 2026
Drug: LBL-024 for Injection; Etoposide Injection and 3 more · For: Advanced Neuroendocrine Carcinoma
Sites: Hefei, China; Beijing, China; Chongqing, China · 25 sites in all
Nanjing Leads Biolabs Co.,LtdIndustry
NCT07111546 · 140 participants (planned) · Start Oct 20, 2025 · Primary completion Dec 26, 2027
Drug: LBL-024 for Injection; Cisplatin Injection and 2 more · For: Advanced Solid Tumour
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 16 sites in all
- A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]Pivotal-lookingRecruiting
Nanjing Leads Biolabs Co.,LtdIndustry
NCT07390383 · 110 participants (planned) · Start Apr 13, 2026 · Primary completion May 30, 2028
Drug: LBL-024 for Injection; Capecitabine tablets and 2 more · For: Advanced Solid Tumour
Sites: Beijing, China; Shijiazhuang, China; Jinan, China · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.